Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses. It focuses solely on human therapeutics and concentrates on medicines based on cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, inflammation and nephrology. In addition to the Company?s marketed products, it has product candidates in mid- to late-stage development in a range of therapeutic areas, including oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. On March 4, 2011, the Company acquired BioVex Group, Inc. On April 7, 2011, it acquired Laboratorio Quimico Farmaceutico Bergamo Ltda (Bergamo). In June 2012, the Company ... (Source: SEC reports)
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen\'s (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive [...]
CAMBRIDGE, Mass., Oct. 6, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and LabCentral today announced that the nomination process to submit proposals to receive an Amgen-sponsored LabCentral Golden [...]
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) and CytomX Therapeutics, Inc., (NASDAQ: CTMX) today announced that the companies [...]
THOUSAND OAKS, Calif., Sept. 25, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today provided an update on Hurricane Maria\'s impact on the Company\'s manufacturing facilities in Puerto Rico. The safety of the [...]
THOUSAND OAKS, Calif., Sept. 11, 2017 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. GMT on Thursday, [...]